Actinium Pharmaceuticals, Inc. (ATNM)

Market Cap	40.24M
Revenue (ttm)	81,000
Net Income (ttm)	-40.92M
Shares Out	31.20M
EPS (ttm)	-1.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,083,367
Open	1.140
Previous Close	1.120
Day's Range	1.125 - 1.290
52-Week Range	1.100 - 10.240
Beta	0.10
Analysts	Strong Buy
Price Target	8.75 (+578.3%)
Earnings Date	Nov 14, 2024

About ATNM

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the Nation...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 49
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: ATNM
• Website: https://www.actiniumpharma.com

Financial Performance

In 2023, Actinium Pharmaceuticals's revenue was $81,000, a decrease of -92.14% compared to the previous year's $1.03 million. Losses were -$48.82 million, 47.9% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ATNM stock is "Strong Buy." The 12-month stock price forecast is $8.75, which is an increase of 578.30% from the latest price.

Price Target

$8.75

(578.30% upside)

Analyst Consensus: Strong Buy